RVU-120 is under clinical development by Ryvu Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RVU-120’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RVU-120 overview

RVU-120 is under development for the treatment of hematological tumors, acute lymphoblastic leukemia, triple negative breast cancer, myeloproliferative disorders, lymphomas including mantle cell lymphoma, myelofibrosis, non-Hodgkin lymphoma, solid tumors including colorectal cancer, breast cancer, prostate cancer, Wilms tumor and rare anemia including Diamond Blackfan anemia (congenital hypoplastic anemia), relapsed/refractory acute myeloid leukemia, diffuse large B-cell lymphoma and myelodysplastic syndrome. The drug candidate is administered through oral route. It acts by targeting Cyclin Dependent Kinase 19 and Cyclin Dependent Kinase 8.

Ryvu Therapeutics overview

Ryvu Therapeutics is a biopharmaceutical company that specializes in novel small molecule therapies addressing high-value emerging targets in precision oncology. Ryvu Therapeutics is headquartered in Krakow, Poland.

For a complete picture of RVU-120’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.